These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36894973)

  • 21. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new tool "
    Shomali W; Gotlib J
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avapritinib for advanced systemic mastocytosis.
    Gotlib J; Reiter A; DeAngelo DJ
    Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
    Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
    Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
    J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
    Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
    Front Immunol; 2018; 9():631. PubMed ID: 29643855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
    Martelli M; Monaldi C; De Santis S; Bruno S; Mancini M; Cavo M; Soverini S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32498255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
    Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
    Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
    Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
    Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
    Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
    Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
    Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis.
    Mannelli F; Crupi F; Zanotti R; Pagano L; Rapezzi D; Tanasi I; Criscuolo M; Bonifacio M; Fresa A; Guglielmelli P; Vannucchi AM
    Ther Adv Hematol; 2023; 14():20406207231205643. PubMed ID: 37929078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant.
    Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH
    Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
    Gotlib J; Kluin-Nelemans HC; Akin C; Hartmann K; Valent P; Reiter A
    Expert Opin Biol Ther; 2021 Apr; 21(4):487-498. PubMed ID: 33063554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.
    Arock M; Wedeh G; Hoermann G; Bibi S; Akin C; Peter B; Gleixner KV; Hartmann K; Butterfield JH; Metcalfe DD; Valent P
    Haematologica; 2018 Nov; 103(11):1760-1771. PubMed ID: 29976735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.